AI Article Synopsis
- Emerging variants of SARS-CoV-2 require updated vaccine antigens, with nucleic acid-based vaccines being preferred due to their ease of modification.
- The study compared the immune responses of DNA vaccines with an approved mRNA vaccine, showing that DNA vaccines elicited strong immune responses similar to those of mRNA-1273.
- The results emphasize the importance of adjuvants in enhancing the effectiveness of DNA vaccines, supporting their use as a fast response option for SARS-CoV-2 and other infectious diseases.
Article Abstract
Emerging variants of SARS-CoV-2 call for frequent changes in vaccine antigens. Nucleic acid-based vaccination strategies are superior as the coding sequences can be easily altered with little impact on downstream production. mRNA vaccines, including variant-specific boosters, are approved for SARS-CoV-2. Here, we tested the efficacy of DNA vaccines against the SARS-CoV-2 Spike aided by the AddaS03 adjuvant using electroporation and compared their immunogenicity with an approved mRNA vaccine (mRNA-1273). DNA vaccination elicited robust humoral and cellular immune responses in C57BL/6 mice with Spike-specific antibody neutralization and T cells produced from 20 μg DNA vaccines similar to that from 0.5 μg mRNA-1273. Furthermore, a Nanoplasmid-based vector further increased the immunogenicity Our results indicate that adjuvants are critical to the efficacy of DNA vaccines in stimulating robust immune responses against Spike, highlighting the feasibility of plasmid DNA as a rapid nucleic acid-based vaccine approach against SARS-CoV-2 and other emerging infectious diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10271916 | PMC |
| http://dx.doi.org/10.1016/j.isci.2023.107120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!